Compare HDRN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HDRN | HURA |
|---|---|---|
| Founded | 2024 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.0M | 160.5M |
| IPO Year | 2024 | 2010 |
| Metric | HDRN | HURA |
|---|---|---|
| Price | $0.75 | $2.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | 83.3K | ★ 250.0K |
| Earning Date | 11-08-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.41 |
| 52 Week High | $2.67 | $3.43 |
| Indicator | HDRN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 26.14 | 59.70 |
| Support Level | N/A | $2.06 |
| Resistance Level | $2.03 | $2.22 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 20.90 | 92.86 |
Hadron Energy Inc is a nuclear technology company focused on developing factory-fabricated, transportable 10 megawatt-electric (MWe) micro-modular reactors (MMRs) to meet the growing demand for clean, reliable, and affordable power. The company aims to deliver scalable, carbon-free energy solutions that can be rapidly deployed to power a variety of industries, including data centers, industrial facilities, remote communities, government installations and more. The market segments for its proprietary reactor, Hadron Halos, are Data Centers, Industrial Facilities and Heavy Manufacturing, Remote Communities and Critical Infrastructure, and Utilities and Distributed Energy.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.